paroxetine

Summary

Summary: A serotonin uptake inhibitor that is effective in the treatment of depression.

Top Publications

  1. Simon J, Portman D, Kaunitz A, Mekonnen H, Kazempour K, Bhaskar S, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013;20:1027-35 pubmed publisher
    The efficacy and safety of low-dose paroxetine 7.5 mg for the treatment of menopausal vasomotor symptoms were evaluated in two multicenter, double-blind, placebo-controlled, phase 3 studies of 12 and 24 weeks' duration...
  2. Mathes C, Spector A. The selective serotonin reuptake inhibitor paroxetine does not alter consummatory concentration-dependent licking of prototypical taste stimuli by rats. Chem Senses. 2011;36:515-26 pubmed publisher
    ..Exogenous administration of the selective serotonin reuptake inhibitor, paroxetine, has been shown to increase taste sensitivity to stimuli described by humans as sweet and bitter...
  3. Boulenger J, Hermes A, Huusom A, Weiller E. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. Curr Med Res Opin. 2010;26:605-14 pubmed publisher
    ..depressive disorder (n = 459) were randomised to 24 weeks of double-blind treatment with escitalopram (20 mg) or paroxetine (40 mg)...
  4. Yoshimura R, Umene Nakano W, Suzuki A, Ueda N, Miyamoto K, Ikenouchi Sugita A, et al. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Hum Psychopharmacol. 2009;24:489-94 pubmed publisher
    ..the relationship between the serotonin transporter gene linked polymorphic regions (5-HTTLPR) or plasma paroxetine levels and clinical response to paroxetine in depressed patients...
  5. Gibiino S, Serretti A. Paroxetine for the treatment of depression: a critical update. Expert Opin Pharmacother. 2012;13:421-31 pubmed publisher
    ..b>Paroxetine represents a widely prescribed and reliable antidepressant for the expert clinician, but the latest data do not ..
  6. Shah M, Kufareva I, Pascual J, Zhang Q, Stout C, Halpert J. A structural snapshot of CYP2B4 in complex with paroxetine provides insights into ligand binding and clusters of conformational states. J Pharmacol Exp Ther. 2013;346:113-20 pubmed publisher
    An X-ray crystal structure of CYP2B4 in complex with the drug paroxetine [(3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine] was solved at 2.14 Å resolution...
  7. Qu S, Huang Y, Zhang Z, Chen J, Lin R, Wang C, et al. A 6-week randomized controlled trial with 4-week follow-up of acupuncture combined with paroxetine in patients with major depressive disorder. J Psychiatr Res. 2013;47:726-32 pubmed publisher
    ..trial with 4-week follow-up, 160 patients with major depressive disorder (MDD) were randomly assigned to paroxetine (PRX) alone (n = 48) or combined with 18 sessions of manual acupuncture (MA, n = 54) or electrical acupuncture (..
  8. Murata Y, Kobayashi D, Imuta N, Haraguchi K, Ieiri I, Nishimura R, et al. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol. 2010;30:11-7 pubmed publisher
    b>Paroxetine discontinuation symptoms can at times be severe enough to reduce the quality of life...
  9. Peng Z, Xue F, Wang H, Zhang R, Chen Y, Wang Y, et al. Paroxetine up-regulates neurogenesis in hippocampus-derived neural stem cell from fetal rats. Mol Cell Biochem. 2013;375:105-13 pubmed publisher
    b>Paroxetine is a widely used antidepressant in clinic. Besides its role in inhibition of serotonin reuptake, resent studies indicate that the increase of hippocampal neurogenesis is also involved in its pharmacology...

More Information

Publications62

  1. Parker R, Soberman J. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol. Pharmacotherapy. 2011;31:630-41 pubmed publisher
    To compare the effects of paroxetine on the pharmacokinetics and pharmacodynamics of the immediate-release (IR) and extended-release (ER) formulations of metoprolol.
  2. Viviani R, Abler B, Seeringer A, Stingl J. Effect of paroxetine and bupropion on human resting brain perfusion: an arterial spin labeling study. Neuroimage. 2012;61:773-9 pubmed publisher
    ..In this study, arterial spin labeling (ASL) was used to quantify the effect of seven days of administration of paroxetine (20 mg), bupropion (150 mg) on cerebral blood flow levels at rest in a double-blind, placebo-controlled ..
  3. Palesh O, Mustian K, Peppone L, JANELSINS M, Sprod L, Kesler S, et al. Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: a trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Sleep Med. 2012;13:1184-90 pubmed publisher
    ..The purpose of this study was to compare the effect of paroxetine to placebo on sleep problems via a secondary data analysis of a RCT designed to compare the effects of ..
  4. Guilloux J, David D, Xia L, Nguyen H, Rainer Q, Guiard B, et al. Characterization of 5-HT(1A/1B)-/- mice: an animal model sensitive to anxiolytic treatments. Neuropharmacology. 2011;61:478-88 pubmed publisher
    ..elevated basal dialysate levels of 5-HT in the DRN and frontal cortex; (iv) an exaggerated response to acute paroxetine administration in microdialysis experiments, and (v) increased basal core body temperature...
  5. Tatonetti N, Denny J, Murphy S, Fernald G, Krishnan G, Castro V, et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther. 2011;90:133-42 pubmed publisher
    The lipid-lowering agent pravastatin and the antidepressant paroxetine are among the most widely prescribed drugs in the world. Unexpected interactions between them could have important public health implications...
  6. Wei F, Crain A, Whitebird R, Godlevsky O, O Connor P. Effects of paroxetine and sertraline on low-density lipoprotein cholesterol: an observational cohort study. CNS Drugs. 2009;23:857-65 pubmed publisher
    ..This study evaluated the effects of paroxetine and sertraline on low-density lipoprotein cholesterol (LDL-C)...
  7. Tamaji A, Iwamoto K, Kawamura Y, Takahashi M, Ebe K, Kawano N, et al. Differential effects of diazepam, tandospirone, and paroxetine on plasma brain-derived neurotrophic factor level under mental stress. Hum Psychopharmacol. 2012;27:329-33 pubmed publisher
    ..Fourteen healthy male volunteers received one of four drugs, diazepam (5?mg), tandospirone (20?mg), paroxetine (10?mg), and matched placebo, in a double-blind, crossover manner...
  8. Mathes C, Gregson J, Spector A. The selective serotonin reuptake inhibitor paroxetine decreases breakpoint of rats engaging in a progressive ratio licking task for sucrose and quinine solutions. Chem Senses. 2013;38:211-20 pubmed publisher
    ..Here, we examined the effect of paroxetine, a selective serotonin reuptake inhibitor, on appetitive responding for a preferred and an avoided taste ..
  9. Homan K, Wu E, WILSON M, Singh P, Larsen S, Tesmer J. Structural and functional analysis of g protein-coupled receptor kinase inhibition by paroxetine and a rationally designed analog. Mol Pharmacol. 2014;85:237-48 pubmed publisher
    Recently we identified the serotonin reuptake inhibitor paroxetine as an inhibitor of G protein-coupled receptor kinase 2 (GRK2) that improves cardiac performance in live animals...
  10. Munno D, Sterpone S, Fania S, Cappellin F, Mengozzi G, Saroldi M, et al. Plasma brain derived neurotrophic factor levels and neuropsychological aspects of depressed patients treated with paroxetine. Panminerva Med. 2013;55:377-84 pubmed
    ..For this reason we investigated the presence of any association between paroxetine treatment, BDNF levels and cognitive performances in depressed patients...
  11. Yasui Furukori N, Nakagami T, Kaneda A, Inoue Y, Suzuki A, Otani K, et al. Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders. Hum Psychopharmacol. 2011;26:602-8 pubmed publisher
    There are few data concerning a clear relationship between the clinical effect of paroxetine and plasma drug concentrations, although therapeutic ranges have been established for some tricyclic antidepressants...
  12. Polak A, Witteveen A, Visser R, Opmeer B, Vulink N, Figee M, et al. Comparison of the effectiveness of trauma-focused cognitive behavioral therapy and paroxetine treatment in PTSD patients: design of a randomized controlled trial. BMC Psychiatry. 2012;12:166 pubmed publisher
    ..common interventions for Posttraumatic Stress Disorder (PTSD) are pharmacological treatment with SSRIs such as paroxetine and psychological treatment such as Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)...
  13. Uguz F, Sonmez E. Neuroleptic malignant syndrome following combination of sertraline and paroxetine: a case report. Gen Hosp Psychiatry. 2013;35:327.e7-327.e8 pubmed publisher
    ..This case report presents a female patient developing NMS following the use of a combination of sertraline and paroxetine.
  14. Kotlyar M, AL ABSI M, Thuras P, VUCHETICH J, Adson D, Nowack A, et al. Effect of paroxetine on physiological response to stress and smoking. Psychosom Med. 2013;75:236-43 pubmed publisher
    ..cardiovascular response to stress is associated with cardiovascular disease risk, this study examined paroxetine's effect on the physiological response to combining stress and smoking...
  15. Stidd D, Vogelsang K, Krahl S, Langevin J, Fellous J. Amygdala deep brain stimulation is superior to paroxetine treatment in a rat model of posttraumatic stress disorder. Brain Stimul. 2013;6:837-44 pubmed publisher
    ..DBS) as a possible novel treatment for PTSD and compare it to current treatment with a commonly used SSRI, paroxetine, in a rat PTSD model...
  16. Menza M, Dobkin R, Marin H, Mark M, Gara M, Buyske S, et al. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Mov Disord. 2009;24:1325-32 pubmed publisher
    ..This was an NIH-funded, randomized, controlled trial of paroxetine, nortriptyline, and placebo. It included an 8 week acute phase and a 16 week blind extension phase...
  17. Pilhatsch M, Wolf R, Winter C, Lewitzka U, Bauer M. Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study. J Affect Disord. 2010;126:453-7 pubmed publisher
    To compare the efficacy and safety of adjunctive treatment with paroxetine or amitriptyline in patients with bipolar disorder who relapsed into a depressive episode during lithium maintenance therapy...
  18. Morag A, Pasmanik Chor M, Oron Karni V, Rehavi M, Stingl J, Gurwitz D. Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics. 2011;12:171-84 pubmed publisher
    ..We screened 80 LCLs from healthy adult female individuals for growth inhibition by paroxetine. A total of 14 LCLs with reproducible high and low sensitivities to paroxetine (seven from each phenotypic group)..
  19. Nardi A, Valenca A, Freire R, Mochcovitch M, Amrein R, Sardinha A, et al. Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Braz J Med Biol Res. 2011;44:366-73 pubmed
    ..naturalistic 8-week study was to compare the efficacy and safety of treatment with clonazepam (N = 63) and paroxetine (N = 57) in patients with panic disorder with or without agoraphobia...
  20. Sela V, Biesdorf C, Ramos D, Zangrossi H, Graeff F, Audi E. Serotonin-1A receptors in the dorsal periaqueductal gray matter mediate the panicolytic-like effect of pindolol and paroxetine combination in the elevated T-maze. Neurosci Lett. 2011;495:63-6 pubmed publisher
    ..The results of a previous study have shown that pindolol potentiates the panicolytic effect of paroxetine in rats submitted to the elevated T-maze (ETM)...
  21. Troost J, Tatami S, Tsuda Y, Mattheus M, Mehlburger L, Wein M, et al. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Br J Clin Pharmacol. 2011;72:247-56 pubmed publisher
    ..To determine the effect of the strong CYP2D6 inhibitor paroxetine and strong CYP3A4 inhibitor ketoconazole on the pharmacokinetics and safety (orthostatic challenge) of ..
  22. Takeuchi K, Tanaka A, Nukui K, Kojo A, Gyenge M, Amagase K. Aggravation by paroxetine, a selective serotonin reuptake inhibitor, of antral lesions generated by nonsteroidal anti-inflammatory drugs in rats. J Pharmacol Exp Ther. 2011;338:850-9 pubmed publisher
    ..c.) 1 h after the refeeding and killed 6 h later. Paroxetine (1-10 mg/kg) was given orally 30 min before indomethacin. Indomethacin caused antral lesions in refed rats...
  23. Lau B, Yau S, Lee T, Ching Y, Tang S, So K. Effect of corticosterone and paroxetine on masculine mating behavior: possible involvement of neurogenesis. J Sex Med. 2011;8:1390-403 pubmed publisher
    ..Adult male rats were treated with corticosterone and/or paroxetine, an antidepressant, for 2 weeks...
  24. Gero D, Szoleczky P, Suzuki K, Módis K, Olah G, Coletta C, et al. Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction. Diabetes. 2013;62:953-64 pubmed publisher
    ..5%. Follow-up studies focused on paroxetine, a clinically used antidepressant compound that has not been previously implicated in the context of ..
  25. Salonia A, Rocchini L, Sacca A, Pellucchi F, Ferrari M, Carro U, et al. Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. J Sex Med. 2009;6:2868-77 pubmed publisher
    ..The aim of this study was to assess the acceptance of and the discontinuation rate from paroxetine treatment in patients with lifelong PE...
  26. Santos P, Scaini G, Rezin G, Benedet J, Rochi N, Jeremias G, et al. Brain creatine kinase activity is increased by chronic administration of paroxetine. Brain Res Bull. 2009;80:327-30 pubmed publisher
    ..modulate energy metabolism, we decided to investigate CK activity from rat brain after chronic administration of paroxetine (selective serotonin reuptake inhibitor), nortriptiline (tricyclic antidepressant) and venlafaxine (selective ..
  27. Murata Y, Kamishioiri Y, Tanaka K, Sugimoto H, Sakamoto S, Kobayashi D, et al. Severe sleepiness and excess sleep duration induced by paroxetine treatment is a beneficial pharmacological effect, not an adverse reaction. J Affect Disord. 2013;150:1209-12 pubmed publisher
    Severe sleepiness and excess sleep duration, "Hypersomnia", induced by paroxetine treatment are generally considered adverse drug reactions, however, our experience indicates that patients with depressive disorder who experience ..
  28. Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, et al. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J Clin Psychopharmacol. 2011;31:638-42 pubmed publisher
    To compare the efficacy and safety of augmenting paroxetine with risperidone, buspirone, valproate, trazodone, or thyroid hormone in patients with treatment-resistant depression (TRD), 225 patients with retrospectively and/or ..
  29. van der Loos M, Mulder P, Hartong E, Blom M, Vergouwen A, van Noorden M, et al. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand. 2010;122:246-54 pubmed publisher
    ..In the second phase of this study paroxetine was added to ongoing treatment in non-responders...
  30. Fiorentini S, Russo D, D Amato A, Limpido L, Bersani G. [Sibutramine-related panic attack: a clinical case of apparent resolution with paroxetine]. Riv Psichiatr. 2009;44:64-7 pubmed
    ..b>Paroxetine and alprazolam were administered to the patient, with the resolution of the anxious symptoms...
  31. Abler B, Seeringer A, Hartmann A, Gron G, Metzger C, Walter M, et al. Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion. Neuropsychopharmacology. 2011;36:1837-47 pubmed publisher
    Sexual dysfunction is a common side effect of selective serotonin reuptake inhibitors (SSRIs) like paroxetine in the treatment of depression, imposing a considerable risk on medication adherence and hence therapeutic success...
  32. Scaini G, Santos P, Benedet J, Rochi N, Gomes L, Borges L, et al. Evaluation of Krebs cycle enzymes in the brain of rats after chronic administration of antidepressants. Brain Res Bull. 2010;82:224-7 pubmed publisher
    ..citrate synthase and succinate dehydrogenase activities from rat brain after chronic administration of paroxetine, nortriptiline and venlafaxine...
  33. van der Loos M, Mulder P, Hartong E, Blom M, Vergouwen A, van Noorden M, et al. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord. 2011;13:111-7 pubmed publisher
    ..we described the efficacy of lamotrigine versus placebo as add-on to lithium (followed by the addition of paroxetine in nonresponders) in the short-term treatment of bipolar depression...
  34. Oved K, Morag A, Pasmanik Chor M, Oron Karni V, Shomron N, Rehavi M, et al. Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. Pharmacogenomics. 2012;13:1129-39 pubmed publisher
    ..Eighty LCLs were screened from healthy adult female individuals for growth inhibition by paroxetine. Eight LCLs exhibiting high or low sensitivities to paroxetine were chosen for genome-wide expression profiling ..
  35. Thal D, Homan K, Chen J, Wu E, Hinkle P, Huang Z, et al. Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol. 2012;7:1830-9 pubmed publisher
    ..Herein we identify the selective serotonin reuptake inhibitor (SSRI) paroxetine as a selective inhibitor of GRK2 activity both in vitro and in living cells...
  36. McHugh P, Rogers G, Glubb D, Joyce P, Kennedy M. Proteomic analysis of rat hippocampus exposed to the antidepressant paroxetine. J Psychopharmacol. 2010;24:1243-51 pubmed publisher
    ..Rats were administered either 5 mg/kg daily of the antidepressant paroxetine or vehicle for 12 days, then hippocampal protein was recovered and resolved by 2-D gel electrophoresis...
  37. Nagata K, Imai T, Yamashita T, Tsuda M, Tozaki Saitoh H, Inoue K. Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief. Mol Pain. 2009;5:20 pubmed publisher
    ..b>Paroxetine exhibited the most powerful inhibition of calcium influx via rat and human P2X4 receptors, with IC50 values of 2...
  38. Whittle N, Li L, Chen W, Yang J, Sartori S, Lubec G, et al. Changes in brain protein expression are linked to magnesium restriction-induced depression-like behavior. Amino Acids. 2011;40:1231-48 pubmed publisher
    ..Aberrant expressions of DDAH1, MnSOD and GDH1 were normalized by chronic paroxetine treatment which also normalized the enhanced depression-like behavior, strengthening the link between the ..
  39. Richard I, McDermott M, Kurlan R, Lyness J, Como P, Pearson N, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78:1229-36 pubmed publisher
    ..A total of 115 subjects with PD were enrolled at 20 sites. Subjects were randomized to receive an SSRI (paroxetine; n = 42), an SNRI (venlafaxine extended release [XR]; n = 34), or placebo (n = 39)...
  40. Schneier F, Neria Y, Pavlicova M, Hembree E, Suh E, Amsel L, et al. Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial. Am J Psychiatry. 2012;169:80-8 pubmed publisher
    ..The authors compared prolonged exposure therapy (a CBT) plus paroxetine (an SSRI) with prolonged exposure plus placebo in the treatment of terrorism-related PTSD...
  41. Wagner K, Marinescu D, Hartmann J, Wang X, Labermaier C, Scharf S, et al. Differences in FKBP51 regulation following chronic social defeat stress correlate with individual stress sensitivity: influence of paroxetine treatment. Neuropsychopharmacology. 2012;37:2797-808 pubmed publisher
    ..stress model both directly after stress and after a recovery period of 3 weeks and also studied the efficacy of paroxetine in this model...
  42. Greeven A, van Balkom A, van der Leeden R, Merkelbach J, van den Heuvel O, Spinhoven P. Cognitive behavioral therapy versus paroxetine in the treatment of hypochondriasis: an 18-month naturalistic follow-up. J Behav Ther Exp Psychiatry. 2009;40:487-96 pubmed publisher
    ..study investigated whether the reduction in hypochondriacal complaints after initial treatment with CBT or paroxetine sustained during a follow-up period and whether psychiatric severity at pretest predicted the course of ..
  43. Cipriani A, Purgato M, Furukawa T, Trespidi C, Imperadore G, Signoretti A, et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012;:CD006534 pubmed publisher
    ..Citalopram, one of the first selective serotonin reuptake inhibitors (SSRI) introduced in the market, is one of these antidepressant drugs that clinicians use for routine depression care...
  44. Wurst K, Poole C, Ephross S, Olshan A. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010;88:159-70 pubmed publisher
    Several studies have evaluated maternal first trimester paroxetine use and the prevalence of congenital defects, particularly cardiac defects. To synthesize current epidemiologic information, a meta-analysis was conducted...
  45. Bakker M, Kerstjens Frederikse W, Buys C, de Walle H, de Jong van den Berg L. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol. 2010;88:94-100 pubmed publisher
    There is a need for case-control studies of the effect of paroxetine on the occurrence of specific heart defects. We performed a case-control study with data from a population-based birth defects registry in the Netherlands...
  46. Nichols A, Fatato P, Shenouda M, Paul J, Isler J, Pedersen R, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol. 2009;49:219-28 pubmed publisher
    ..P450 (CYP) 2D6 substrates to interact with desvenlafaxine (administered as desvenlafaxine succinate) and paroxetine was evaluated...
  47. Dick I, Brochu R, Purohit Y, Kaczorowski G, Martin W, Priest B. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J Pain. 2007;8:315-24 pubmed
    ..By contrast, fluoxetine, paroxetine, mianserine, and zimelidine had IC(50)s for Na(V)1...
  48. Kobayashi T, Washiyama K, Ikeda K. Inhibition of G protein-activated inwardly rectifying K+ channels by the antidepressant paroxetine. J Pharmacol Sci. 2006;102:278-87 pubmed
    b>Paroxetine is commonly used as a selective serotonin reuptake inhibitor for the treatment of depression and other psychiatric disorders. However, the molecular mechanisms of the paroxetine effects have not yet been sufficiently clarified...
  49. Bazzichi L, Giannaccini G, Betti L, Mascia G, Fabbrini L, Italiani P, et al. Alteration of serotonin transporter density and activity in fibromyalgia. Arthritis Res Ther. 2006;8:R99 pubmed
    ..SERT expression and functionality were evaluated through the measurement of [3H]paroxetine binding and the [3H]serotonin uptake itself...
  50. Yamaguchi T, Hidaka N, Suemaru K, Araki H. The coadministration of paroxetine and low-dose aspirin synergistically enhances gastric ulcerogenic risk in rats. Biol Pharm Bull. 2008;31:1371-5 pubmed
    b>Paroxetine is often coadministered with low-dose aspirin to treat cerebral infarction patients with depression...
  51. Tadic A, Muller M, Rujescu D, Kohnen R, Stassen H, Dahmen N, et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:325-31 pubmed
    ..association of the MAOA T941G gene variant with differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with major depression (DSM-IV criteria) participating in a randomized double-blind controlled ..
  52. Guilloux J, David D, Guiard B, Chenu F, Reperant C, Toth M, et al. Blockade of 5-HT1A receptors by (+/-)-pindolol potentiates cortical 5-HT outflow, but not antidepressant-like activity of paroxetine: microdialysis and behavioral approaches in 5-HT1A receptor knockout mice. Neuropsychopharmacology. 2006;31:2162-72 pubmed
    Selective serotonin reuptake inhibitors like paroxetine (Prx) often requires 4-6 weeks to achieve clinical benefits in depressed patients...
  53. Kennedy S, Fulton K, Bagby R, Greene A, Cohen N, Rafi Tari S. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry. 2006;51:234-42 pubmed
    ..women with major depressive disorder (MDD) before and during treatment with bupropion sustained release (SR) or paroxetine. The secondary objectives involved a comparative evaluation of the Sex Effects Scale (Sex FX) and the ..